Answers are grounded in this paper and cite their sources.
motion sickness (kinetosis) is a common and temporarily incapacitant ailment, manageable with behavioral as well as pharmacological measures. to assess the effectiveness and safety of a combination of gamma-aminobutyric acid, glutamic acid, calcium, thiamine, pyridoxine, and cyanocobalamin (Group A) (nA=170) and extract of Zingiber officinale (ginger) (Group B) (nB=165) in the management of chronic complaints consistent with motion sickness. both Groups were tested according to the following endpoints, under self-paired as well as comparative study designs: (1) reduction of ≥20 score points in the total MSAQ score, (2) percentage of patients presenting a reduction of the total MSAQ score, (3) absolute MSAQ score reduction, (4) physician's assessment scores (5) final overall assessment of study medication and (6) willingness to continue treatment. Safety was also evaluated. there was a statistically significant better performance under both study designs for Group A (p=0.05; different statistical tests) in all endpoints. Both regimens were safe, with different neurological and gastrointestinal tolerability outcomes. (1) Group A and Group B regimens were effective and safe in the management of chronic complaints consistent with motion sickness and (2) Group A regimen was more effective than Group B. ClinicalTrials.gov ID: NCT05221892.
No takes yet. Share an insight, caveat, or question.
Nunes et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: